BOTHELL,
Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife
Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the
"Company"), a leading developer and supplier of bioproduction tools
and services for the cell and gene therapy (CGT) market, announces
the appointment of Tony J. Hunt,
Executive Chairman of Repligen Corporation (Nasdaq: RGEN) and a
recognized leader in bioprocessing innovation, to its board of
directors effective January 2, 2025.
His appointment increases board membership to six.
"Tony is highly respected in the life sciences industry with
decades of accomplishments, and it is an honor he has agreed to
serve on our board," said Roderick de
Greef, Chairman and CEO of BioLife. "He brings to BioLife an
impressive record of success in our sector that culminated in
establishing Repligen as a technology leader in bioprocessing.
While at Repligen, he led the company to consistently exceed
industry revenue growth through a strategy of disciplined
acquisitions, internal product development and commercial
execution. We look forward to calling upon his expertise as we
focus on extending BioLife's position as a provider of industry
leading solutions for bioproduction workflows to the CGT
market."
"I am excited to be joining BioLife at a critical time in their
evolution," said Tony Hunt.
"Rod and his team have made huge strides over the last year
rationalizing and reprioritizing the portfolio by focusing the
Company on cell processing solutions in CGT. I look forward to
working with the BioLife team to further drive growth and
innovation in the CGT bioprocessing market."
Prior to being named Executive Chairman of Repligen in
September 2024, Mr. Hunt served as
CEO and director for nine years, having joined the firm in 2014 as
Chief Operating Officer. Earlier, he was President of Bioproduction
at Life Technologies, a global life sciences company acquired by
Thermo Fisher Scientific in 2014. He joined Life Technologies in
2008 as General Manager of Bioproduction Chromatography and Pharma
Analytics. From 2000 to 2008, Mr. Hunt was Senior Director of
Pharma Programs at Applied Biosystems, where he launched the Pharma
Analytics business that became part of the Bioproduction platform
at Life Technologies.
He holds a bachelor's degree with honors in microbiology and a
master's degree in biotechnology from the University of Galway, and
an MBA from the Questrom School of Business at Boston
University. Mr. Hunt serves on the board of directors of 908
Devices Inc., a publicly traded innovator of handheld and desktop
devices for chemical analysis.
About BioLife Solutions
BioLife Solutions is a
leading supplier of cell processing tools and services for the cell
and gene therapy (CGT) market. Our expertise facilitates the
commercialization of new therapies by supplying solutions that
maintain the health and function of biologic materials during the
collection, development, storage and distribution. For more
information, please visit www.biolifesolutions.com, and
follow BioLife on LinkedIn and X.
Media & Investor Relations
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
Alliance Advisors IR
Jody Cain
(310) 691-7100
jcain@allianceadvisors.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-appoints-tony-j-hunt-to-its-board-of-directors-302332536.html
SOURCE BioLife Solutions, Inc.